Brolucizumab 6 mg + Aflibercept 2 mg
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Retinal Vein Occlusion
Conditions
Central Retinal Vein Occlusion
Trial Timeline
Jul 3, 2019 → Jul 26, 2021
NCT ID
NCT03810313About Brolucizumab 6 mg + Aflibercept 2 mg
Brolucizumab 6 mg + Aflibercept 2 mg is a phase 3 stage product being developed by Novartis for Central Retinal Vein Occlusion. The current trial status is terminated. This product is registered under clinical trial identifier NCT03810313. Target conditions include Central Retinal Vein Occlusion.
What happened to similar drugs?
4 of 19 similar drugs in Central Retinal Vein Occlusion were approved
Approved (4) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04005352 | Phase 3 | Completed |
| NCT03810313 | Phase 3 | Terminated |
| NCT03802630 | Phase 3 | Terminated |
| NCT03386474 | Phase 3 | Completed |
Competing Products
20 competing products in Central Retinal Vein Occlusion